BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Programmed cell death protein 1
1
Roles of the tumor microenvironment in the resistance to programmed cell death protein 1 inhibitors in patients with gastric cancer
9/9/2024 8:41:20 AM | Browse: 183 | Download: 711
2
Human epidermal growth factor receptor 2 expression level and combined positive score can evaluate efficacy of advanced gastric cancer
5/21/2024 7:25:52 AM | Browse: 139 | Download: 952
3
Hepatic arterial infusion chemotherapy with/without anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis
1/26/2024 7:56:29 AM | Browse: 496 | Download: 1607
4
Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses
12/14/2023 5:08:46 AM | Browse: 334 | Download: 1138
5
Immunotherapy in combination with chemotherapy for Peutz-Jeghers syndrome with advanced cervical cancer: A case report
3/27/2023 2:19:30 PM | Browse: 416 | Download: 1070
6
Hypophysitis induced by anti-programmed cell death protein 1 immunotherapy in non-small cell lung cancer: Three case reports
10/21/2022 2:24:59 AM | Browse: 658 | Download: 1623
7
Tsunami of immunotherapy reaches mesothelioma
4/22/2022 8:49:02 AM | Browse: 780 | Download: 1726
8
Recurrent undifferentiated embryonal sarcoma of the liver in adult patient treated by Perbrolizumab: A case report
3/30/2021 8:56:50 AM | Browse: 657 | Download: 2109
9
Exploring the food-gut axis in immunotherapy response of cancer patients
9/4/2020 7:25:49 AM | Browse: 1076 | Download: 2295
10
Immune checkpoint inhibitor-induced colitis: A comprehensive review
2/26/2019 9:05:11 AM | Browse: 1167 | Download: 2116
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.